ClinicalTrials.gg
RecruitingNCT06967194Updated May 28, 2025

Early Beta Blocker Administration in STEMI Patients With SCAI B Status

An interventional study of Metoprolol (MET) and Plcacebo in ST Segment Elevation Myocardial Infarction (STEMI) and Cardiogenic Shock Post Myocardial Infarction, sponsored by Tel-Aviv Sourasky Medical Center. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Tel-Aviv Sourasky Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies in ST Elevation Myocardial Infarction with a site in Israel — 1 open to participants now, 2 under way, none of them phase 3. ST Elevation Myocardial Infarction · Israel.

Planned enrollment
7th of 15
200 · median 106
Started
2025
the only one that year
No phase
7 of 20
1 open now
Registered
20th of 20
by date
Lead sponsor
2 of 20
Tel-Aviv Sourasky Medical Center

Among the 20 studies in ST Elevation Myocardial Infarction with a site in Israel, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 7 with no phase, and was the 20th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 200 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

1 of the 20 studies in ST Elevation Myocardial Infarction with a site in Israel is open now.

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in ST Elevation Myocardial Infarction with a site in Israel, or all of them as a file.
02

Study summary

This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.

When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.

During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.

The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.

Read the detailed description

A prospective, randomized, double-blind cohort study will be conducted on patients with STEMI who are hospitalized in the cardiac intensive care unit and classified as SCAI B at the time of admission by the attending physician. Patients will be identified upon admission to the unit and randomized into two arms - a control group and an intervention group. Randomization will be performed using sealed envelopes. A block randomization model will be used based on LVEF estimation of >40% or ≤40%.

In the intervention group, patients will receive standard beta-blocker treatment, specifically low-dose metoprolol at 25 mg twice daily. In the control group, patients will receive a placebo. All other standard treatments will be identical between the two study groups, in accordance with the unit's treatment protocol and the clinical status of the patients.

As an integral part of this treatment, patients will be continuously monitored for parameters including blood pressure, heart rhythm, and blood lactate levels.

The treatment duration under this protocol will be 72 hours or until the occurrence of the primary outcome, whichever comes first. The primary outcome is defined as progression of the patient's condition to SCAI C, according to accepted criteria, including an increase in lactate levels, a decrease in urine output, or a change in mental status. Per guidelines, every 24 hours, investigators will re-evaluate each patient. If they meet current criteria for beta-blocker administration (SCAI A status and no contraindications), the study drug will be terminated and active metoprolol will be prescribed.

To ensure patient safety, the treating staff will have the option to request unblinding of the patient's allocation at any time. Additionally, after the enrollment of 100 patients (or after one year, whichever comes first), an interim analysis of the data will be conducted to ensure the study remains within established safety parameters.

An echocardiogram and follow-up visit will be performed at 30 days.

03

Conditions studied

  • ST Segment Elevation Myocardial Infarction (STEMI)
  • Cardiogenic Shock Post Myocardial Infarction

Keywords

  • acute MI
  • stemi
  • beta blockers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by , clinical signs, and coronary catheterization.
  • Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and/or hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output >0.5 mL/kg/hour).
  • Age 18 years or older.
  • Mentally competent to provide , understand the study procedures, and comply with medical recommendations.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Inability to provide .
  • Evidence of pulmonary edema.
  • Bradycardia (heart rate \<60 beats per minute).
  • PR interval >240 milliseconds.
  • Second- or third-degree atrioventricular (AV) block.
  • Active asthma.
  • Known to metoprolol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Intervention

    Patients treated with Metoprolol 25mg

    Drug: Metoprolol (MET)

  • Placebo comparator
    Placebo

    Patients treated with matching placebo

    Drug: Plcacebo

Interventions

  • DrugMetoprololStudies of MetoprololMetoprolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administration of metoprolol 25 mg twice daily

    Also known as: metoprolol 25mg

  • DrugPlcacebo

    Administration of matching placebo

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Number of patients progressed from SCAI B to SCAI C

    number of patients who progressed from SCAI B to SCAI C as measured by - Serum lactate levels \> mmol/L urinary output \> 0.5 ml/kg/hour slow capillary filling Change in mental status

    Time frame: 3 days from enrollment

Secondary outcomes

  1. Rate of in-hospital mortality

    The mortality rate of patients during index admission

    Time frame: during index admission - expected up to 7 days

  2. Need for Mechanical ventilation

    The rate of patients that will require mechanical ventilation

    Time frame: During index admission - expected up to 7 days

  3. Minor adverse events

    minor events including tachyarrhythmia, bradyarrhythmia, AV blocks

    Time frame: 3 days from enrollment

  4. Hospitalizion duration

    Time of index hospitalization

    Time frame: During index admission - expected up to 7 days

  5. Ejection fraction at 30 days

    Ejection fraction as measured by echocardiography at 30 days

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pizarro G, Fernandez-Friera L, Fuster V, Fernandez-Jimenez R, Garcia-Ruiz JM, Garcia-Alvarez A, Mateos A, Barreiro MV, Escalera N, Rodriguez MD, de Miguel A, Garcia-Lunar I, Parra-Fuertes JJ, Sanchez-Gonzalez J, Pardillos L, Nieto B, Jimenez A, Abejon R, Bastante T, Martinez de Vega V, Cabrera JA, Lopez-Melgar B, Guzman G, Garcia-Prieto J, Mirelis JG, Zamorano JL, Albarran A, Goicolea J, Escaned J, Pocock S, Iniguez A, Fernandez-Ortiz A, Sanchez-Brunete V, Macaya C, Ibanez B. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). J Am Coll Cardiol. 2014 Jun 10;63(22):2356-62. doi: 10.1016/j.jacc.2014.03.014. Epub 2014 Mar 30. PubMed 24694530 ↗
  • Roolvink V, Ibanez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, Dambrink JE, Escalera N, Lipsic E, Albarran A, Fernandez-Ortiz A, Fernandez-Aviles F, Goicolea J, Botas J, Remkes W, Hernandez-Jaras V, Kedhi E, Zamorano JL, Navarro F, Alfonso F, Garcia-Lledo A, Alonso J, van Leeuwen M, Nijveldt R, Postma S, Kolkman E, Gosselink M, de Smet B, Rasoul S, Piek JJ, Fuster V, van 't Hof AWJ; EARLY-BAMI Investigators. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016 Jun 14;67(23):2705-2715. doi: 10.1016/j.jacc.2016.03.522. Epub 2016 Apr 3. PubMed 27050189 ↗
  • Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Juni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191. No abstract available. PubMed 37622654 ↗

Individual participant data

Plan to share: No — Privacy of participants

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 134 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 24 months is below that.

Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 13, 2025
StartActual
May 21, 2025
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06967194
Responsible party
Sponsor
First posted
May 13, 2025
Start date
May 21, 2025
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 28, 2025

Study contacts

Shir Frydman, MD
Contact
shirfrydman@gmail.com
0544267898
Yishay Szekely, MD
Contact
yishay.szekely@gmail.com
Yishay Szekely, MD
principal investigator · Tel-Aviv Sourasky Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metoprolol

Start the discussion